NCT03805932 · OUTCOME

Duration of Response (DOR)

Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia · Source last updated 2026-06-29

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: 28-42 days after day 1 of the last treatment.

What was measured

DOR is defined as the time of initial response until documented tumor progression. Response was assessed by the and is defined as an increase in symptoms or \>25% decline in hematologic parameters related to disease, based on the judgement of the principal investigator. ≥50% increase in sum of products of perpendicular diameters of evaluable (\> 2cm) lymphadenopathy or appearance of new evaluable lymph nodes \> 2 cm short axis.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

anticipated Posting Date: 2029-06
denom Units Selected: Participants
description: DOR is defined as the time of initial response until documented tumor progression. Response was assessed by the and is defined as an increase in symptoms or \>25% decline in hematologic parameters related to disease, based on the judgement of the principal investigator. ≥50% increase in sum of products of perpendicular diameters of evaluable (\> 2cm) lymphadenopathy or appearance of new evaluable lymph nodes \> 2 cm short axis.
reporting Status: NOT_POSTED
time Frame: 28-42 days after day 1 of the last treatment.
title: Duration of Response (DOR)
type: SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice